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WS20.1 Target minority bacterial population in cystic ﬁbrosis lung
microbiota
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1Aix-Marseille Univ, URMITE CNRS-IRD-INSERM UMR 6236, Me´diterrane´e
Infection, Marseille, France
Staphylococcus aureus is one of the most frequently encountered species in Cystic
Fibrosis (CF) lung microbiota. However its frequent presence on agar plates from
sputum samples of CF patients likely impaired the culture of other minority
bacterial species that may be responsible for lung exacerbations. In order to
discover this minority bacterial population, we examined the sputum sample of
a CF patient using conventional culture dependent with or without inhibition of
S. aureus growth with vancomycin and compare our results to culture independent
molecular techniques. Using standard cultures as well as selective media at different
physico-chemical conditions, we isolate Staphylococcus aureus in the majority
of our culture conditions and media. Interestingly, after pre-incubation of the
sample with Vancomycin to inhibit Staphylococcus aureus growth, we isolate
new bacterial species (Granulicatella, Streptococcus, Rothia, Lactobacillus and
Propionibacterium species), especially Actinomyces radicidentis, a rare bacterial
species associated with endodontic infections never described in the context of
CF. Using 16S rDNA PCR ampliﬁcation and sequencing of subsequent clones, we
identiﬁed Streptococcus, Granulicatella, Rothia, Abiotropha, Peptostreptococcus,
Lachnospiraceae and Actinomyces along with S. aureus conﬁrming the culture
dependent ﬁndings. In conclusion, the use of various bacterial inhibitors to inhibit
the growth of the dominant bacteria may help to discover the minority bacterial
population that could be new or emerging species in the context of CF.
WS20.2 A novel gyrB sequence cluster approach for the identiﬁcation
of multiple CF pathogens
D. Kenna1, K. Fuentes1, N. Mustafa1, K. Martin1, J. Turton1. 1Health Protection
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The accurate identiﬁcation of CF pathogens is critical for surveillance purposes,
the monitoring of infection prevalence trends, and for optimising treatment options.
In many cases identiﬁcation by molecular means is a necessity. As a reference
laboratory we are routinely required to identify a wide range of CF pathogens
submitted from hospitals in the UK. Depending on the organism, CF isolates sent
to our laboratory are identiﬁed using species-speciﬁc PCR assays, sequencing, fatty
acid analysis or 16S rDNA sequencing. This multi-faceted approach to identiﬁcation
can be laborious. Our aim in this study was to identify a house-keeping gene
common to multiple pathogens, and to develop a sequenced based assay which
would facilitate rapid identiﬁcation. A number of studies have recently highlighted
the effectiveness of gyrB as a target for the identiﬁcation of individual CF pathogens.
We therefore aligned gyrB sequences from common CF pathogens and designed
degenerate PCR primers which simultaneously detect species of Achromobacter,
Ralstonia and Pandoraea, in addition to the Burkholderia cepacia complex and
Pseudomonas aeruginosa. Those isolates producing positive amplicons in this
assay are then sequenced and clustered with type strains of these species using
BioNumerics software. Sequence clustering with these primers has resulted in
clearly deﬁned clusters both of each individual genus, and for species within that
genus, and has therefore signiﬁcantly improved the speed with which we can identify
many of these organisms.
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Introduction: Precise bacterial identiﬁcation is central to infection management
and epidemiology. Gram negative non-fermenting bacteria (NFB) causing chronic
infection in bronchiectasis undergo phenotypic change, hindering biochemical
identiﬁcation methods. Moreover, these methods may misidentify species from
genera rare in other conditions.
Method: We tested 68 NFB from 44 adults (24 with CF and 20 with non-CF
bronchiectasis). A subset were selected because biochemical reactions (API 20 NE,
bioMe´rieux) gave no identity, or identiﬁed an unusual species. Isolates were anal-
ysed by MALDI-TOF (Bruker). National reference laboratory (RL) identiﬁcation
was by PCR or MIDI.
Results: MALDI identiﬁed 67/68 bacteria to species level. Formic acid ex-
traction added no beneﬁt. MALDI identiﬁcation was correct to species level
in 38/48 RL-conﬁrmed isolates, with 10 isolates from 8 patients discrepant as
follows (RL/MALDI): Stenotrophomonas maltophilia /Pseudomonas geniculata;
Achromobacter xylosoxidans/A.denitriﬁcans; P. alcaligenes/P. oleovorans; Borde-
tella sp./no identity; B. sp/B. bronchiseptica; B. sp/B. parapertussis; Aeromonas
sp./A. caviae; P. ﬂuorescens or putida/P. monteilii. MALDI correctly identiﬁed
all 18 RL-conﬁrmed P. aeruginosa, where API 20 NE had given no (5) or
wrong (13) results, incorrectly selecting genera such as Moraxella, Comamonas,
and Photobacterium. MALDI-TOF analysis is more reliable than API 20 NE in
adult bronchiectasis, with great potential for fast, accurate identiﬁcation in clinical
practice.
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Objective: To show the faster PA detection provided by sputum culture in conjunction
with RT-PCR compared to routine sputum culture alone in the screening of CF patients.
Methods: A French prospective multicenter study (2008–2011) was conducted in three
specialized CF centers in Brittany. Only patients PA-free for at least one year were
included [Never and Free patients according to the deﬁnition of Lee et al. (Lee et
al., 2003)]. For each patient, sputum was collected every three months and clinical
and bacteriological analyses were performed. A routine bacteriological culture was
performed according to the French standard guidelines. PA was investigated directly
on sputa by quantitative RT-PCR targeting the oprL gene. Each positive or doubtful
oprL RT-PCR was controlled by the multiplex gyrB/ecf X RT-PCR.
Results: Ninety seven patients were enrolled and 757 samples analyzed. By culture,
40 patients were PA-positive: 14 Never patients and 26 Free patients. In 18 cases,
both RT-PCR and routine culture were positive. In 20 cases, RT-PCR gave an earlier
detection of PA than routine culture alone. In 2 cases, RT-PCR failed to detect PA. The
median of time saving achieved through the PCR was 8 months ranging from 12 days
to 38 months. The RT-PCR was even more powerful for Never patients (time saving
of 16 months versus 6 months for Free patients).
Conclusion: This study indicates that PCR assay is an optimal PA screening technique,
saving an average of 8 months in early detection over conventional culture. Given that
the antibiotic therapy onset may depend on PCR results, we suggest further evaluation
of the impact of our PA screening results on CF patient management.
